Parallel Industries (EAPH) Stock Price

Parallel Industries Price

OTC·CLOSED
0.00
-0.0000 (-0.00 %)
Market closed

Over the last 18 years Parallel Industries grew revenue by 9.6% annually, reaching 1.56 M USD. For Parallel Industries, the net margin of -20.8% is up versus -535.2% a few years ago.

Parallel Industries stock price

Access this data via the Eulerpool API

Parallel Industries business model & stock analysis

Easton Pharmaceuticals Inc. is a Canada-based company specializing in the healthcare sector and alternative medicines. It was founded in 1997 and has been listed on the Canadian Securities Exchange since 2014. The company distributes its products in the United States, Canada, Mexico, Europe, and Asia, offering a wide range of products and services including medications, medical devices, cosmetics, supplements, and agricultural products. It operates in various sectors such as the pharmaceutical industry, cosmetics industry, agricultural industry, and medical devices industry. The main business areas of the company are pharmaceuticals and cosmetic products, offering medications for neuropathic pain, chronic fatigue pain, arthritis, as well as cosmetic products with organic ingredients tailored to specific skin needs. Easton Pharmaceuticals also has a presence in the agricultural market, providing fertilizers and pesticides to promote plant growth and increase crop yields. Additionally, the company offers medical devices such as wound dressings, splints, and bandages for injury treatment. It has also invested in real estate for the development of large shopping centers and hotels. The company's business model focuses on providing products and services specifically tailored to the needs of individuals preferring alternative medicines and beauty products. Easton Pharmaceuticals continually strives to expand its brands and introduce new products to the market, while collaborating with other companies to find innovative solutions to medical and health-related problems. In 2020, Easton Pharmaceuticals entered the cannabis sector by signing an agreement with a Canadian company for hemp seed production and marketing. Overall, Easton Pharmaceuticals is a multi-sector company aiming to offer products and services tailored to specific individuals' needs, with a reputation in the industry and a commitment to expanding its presence in the future.

Frequently asked questions about Parallel Industries

The business model of Easton Pharmaceuticals Inc. is primarily focused on acquiring, developing, and marketing various healthcare products. With a diversified portfolio, the company collaborates with industry professionals and utilizes innovative technologies to bring novel products to market. Easton Pharmaceuticals Inc. aims to enhance human wellness and quality of life by addressing unmet medical needs and exploring potential strategic partnerships within the healthcare sector.

Easton Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The main competitors of Easton Pharmaceuticals Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc, and Novartis AG.

Easton Pharmaceuticals Inc is a renowned pharmaceutical company with a rich history and background. Established in 1997, the company has been at the forefront of developing and distributing innovative healthcare solutions. With a focus on therapeutic drugs and skincare products, Easton Pharmaceuticals has garnered a reputation for delivering high-quality treatments to consumers worldwide. The company is dedicated to research and development, working closely with medical professionals to address unmet needs in various therapeutic areas. Easton Pharmaceuticals Inc's commitment to excellence and dedication to improving global health has propelled its success and solidified its position in the pharmaceutical industry.

Easton Pharmaceuticals Inc has achieved significant milestones since its inception. The company has successfully expanded its product portfolio to include a wide range of pharmaceuticals and healthcare products. Easton Pharmaceuticals Inc has also established strategic partnerships and collaborations with leading industry players, enhancing its market presence and capabilities. Furthermore, the company has demonstrated continuous growth in revenue and shareholder value through its successful business operations. With a strong commitment to innovation and quality, Easton Pharmaceuticals Inc continues to achieve remarkable milestones and advance in the pharmaceutical industry.

Easton Pharmaceuticals Inc is primarily present in North America, with a strong focus on Canada and the United States. As a pharmaceutical company, Easton Pharmaceuticals Inc operates within these countries and regions, actively engaging in the development, marketing, and distribution of various healthcare products. With its headquarters located in Toronto, Canada, Easton Pharmaceuticals Inc has established a reputable presence in the North American pharmaceutical market, while continually seeking opportunities for growth and expansion within these regions.

Easton Pharmaceuticals Inc represents a strong commitment to innovation, growth, and excellence in the pharmaceutical industry. The company's core values include integrity, transparency, and a customer-centric approach. With a focus on delivering high-quality healthcare solutions, Easton Pharmaceuticals Inc strives to improve patient outcomes and enhance well-being. The company embraces a corporate philosophy driven by research and development, fostering strategic partnerships, and expanding its global footprint. By combining scientific expertise with a dedication to ethical business practices, Easton Pharmaceuticals Inc aims to pave the way for advanced pharmaceutical solutions that meet the evolving needs of the healthcare market.

Converted at the current exchange rate, the Parallel Industries share trades at 0.00 EUR (0.00 USD).

Easton Pharmaceuticals Inc is a Canadian company specializing in the development and marketing of proprietary drugs, medical devices, and diagnostic products. The company operates in multiple sectors and offers a wide range of products. One of Easton Pharmaceuticals' sectors is the development of women's drugs. The company has focused on developing products for the treatment of cervical cancer and HPV. It has signed an exclusive licensing agreement with a leading European pharmaceutical company to develop a series of new HPV tests and treatments. In another sector, the company offers products for the treatment of pain and inflammation. This includes the medication "Nasutra," an effective natural remedy used for erectile dysfunction and sexual dysfunction. Easton Pharmaceuticals has also developed tissue repair technology to help heal injuries and wounds. Additionally, the company specializes in the development of medical devices. This includes a new coating process used in the production of medical devices and implants. The company has also developed a series of diagnostic products that help detect diseases such as lung cancer, breast cancer, and prostate cancer early. Another significant business area for Easton Pharmaceuticals is the marketing of various pharmaceutical products in Canada and the global market. This includes a wide range of prescription medications used in various therapy areas such as pain management, neurology, oncology, and gastroenterology. To manage and coordinate these different sectors, the company has built a strong leadership team. It relies on effective teamwork based on a combination of expertise and critical skills. The focus on quality and customer orientation is another important factor contributing to the success of Easton Pharmaceuticals. In addition to these sectors, the company also has a vision focused on innovation and research. Easton Pharmaceuticals recognizes the close connection between the pharmaceutical industry and the healthcare sector as a whole. Therefore, the company's goal is to identify and leverage research and development opportunities to develop innovative and groundbreaking products. Overall, Easton Pharmaceuticals has a diverse business model focused on the development and marketing of innovative products to promote people's health and well-being. Through leadership by an experienced team, a focus on quality and customer orientation, and investment in research and innovation, the company is on a path to success in the pharmaceutical industry.

The revenue cannot currently be calculated for Parallel Industries.

The profit cannot currently be calculated for Parallel Industries.

The P/E ratio cannot be calculated for Parallel Industries at the moment.

The P/S cannot be calculated for Parallel Industries currently.

The Eulerpool Quality Score for Parallel Industries is 1/10.

The ISIN of Parallel Industries is US2777741057. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Parallel Industries is A1CUUH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Parallel Industries is EAPH. The ticker symbol is used to trade Parallel Industries shares on the stock exchange.

Parallel Industries paid dividends every year for the past 0 years.

Parallel Industries is assigned to the 'Health' sector.

The dividends of Parallel Industries are distributed in USD.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
USD
Initial public offering
Sep 29, 2000
ISIN
US2777741057
Cusip
277774105
Sedol
B4QK1S6
Market capitalization
30,000.00 USDMicro Cap
52-Week Range
0.00–0.00USD
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-2.01 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-0.00 USD
Net Debt / EBIT
-13.17
Debt/Equity
0.36
Last updated Sep 27, 2026, 9:12 PM

Parallel Industries Ticker

OTC · EAPHOTC · EAPH

Parallel Industries FIGI

EAPH:US · BBG000BRG367EAPH:PQ · BBG000BRG875EAPH:UV · BBG000BRG8M8EAPHGBP:XS · BBG00L9H3RX7EAPHGBP:XH · BBG00L9H3S01EAPHGBP:XF · BBG00L9H3S29EAPHGBP:XE · BBG00L9H3S47EAPHGBP:XJ · BBG00L9H3S56EAPHGBP:XL · BBG00L9H3S65EAPHGBP:XG · BBG00L9H3S74EAPHGBP:XO · BBG00L9H3S83EAPHGBP:XA · BBG00L9H3SF5